Virosomes as drug delivery system: An updated review
Article Sidebar
-
Drug Delivery System, Structure, Application, Mechanism, Influenza Virosomes
Abstract
Amid the era of development in all sphere of Biotechnology, Biochemistry and Pharmacology, it would not be an exaggeration to say that we have a myriad of molecules available to us in labs with promising results against many diseases. The limitation lies in the fact that some molecules are toxic when they act on organs other than their targets. Yet others cannot reach their targets in the desired concentration, be it due to easy degradation in the gut or high first-pass metabolism or very short half-life, etc. Thus, to overcome this, we have an alternate drug delivery system, namely Virosomes. The purpose of this review is to understand the drug delivery aspect of the virosomes, its type, structure, method of preparation, mechanism of action, administration routes and the application in the medical field. Virosomes are the regenerated viral envelope having a central empty space that can act as the vehicles for drug delivery. The central empty space can be filled with the desired bioactive molecule. Virosomes are most commonly prepared by using the reconstituted viral envelope of the Influenza virus, but other virus such as Sendai or HVJ, Hepatitis B Virus, HIV, New castle Disease Virus etc., can also be used for the preparation of virosomes. Virosomes has a great potential as the drug delivery system for almost all types of the drugs, and this encourages the researchers and therapeutic industries to enhance their pharmacological profiles, clinical result and stability.
Full text article
References
Almeida, J. D. 1975. Formation of Virosomes from Influenza Subunits and Liposomes. The Lancet, 306(7941):899–901.
Asano, A., Asano, K. 1982. Viral proteins in cell fusion. The Tokai journal of experimental and clinical medicine, (7):193–196.
Beg, S. 2013. Colloidal Drug Delivery Systems in Vaccine Delivery. Current Drug Targets, 14(1):123–137.
Bengtsson, K. L., et al. 2016. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice. Vaccine, 34(16):1927–1935.
Bhattacharya, S., Mazumder, B. 2011. Virosomes: A novel strategy for drug delivery and targeting. BioPharm International, 24(1 Supple 1).
Blom, R. A. M. 2017. Pulmonary delivery of virosome-bound antigen enhances antigen-specific CD4+ T cell proliferation compared to liposome-bound or soluble antigen. Frontiers in Immunology, 8:359.
Bron, R., Ortiz, A., Wilschut, J. 1994. Cellular Cytoplasmic Delivery of a Polypeptide Toxin by Reconstituted Influenza Virus Envelopes (Virosomes). Biochemistry, 33(31):9110–9117.
Bungener, L. 2002. Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine, 20(17-18):2287–2295.
Cassone, A., Casadevall, A. 2012. Recent progress in vaccines against fungal diseases. Current Opinion in Microbiology, 15(4):427–433.
Cech, P. G. 2011. Virosome-formulated plasmodium falciparum AMA-1 and CSP derived peptides as malaria vaccine: Randomized phase 1b trial in semi-immune adults and children. PLoS ONE, 6(7):e22273.
Chang, H. I., Yeh, M. K. 2012. Clinical development of liposome-based drugs: Formulation, characterization, and therapeutic efficacy. International Journal of Nanomedicine, 7:49–60.
Cornet, B., et al. 1990. Virosomes reconstituted from Human Immunodeficiency Virus proteins and lipids. Biochemical and Biophysical Research Communications, 167(1):222–231.
Curran, J., Kolakofsky, D. 1999. Replication of paramyxoviruses. Advances in virus research, 54:403–422.
Cusi, M. G. 2006. Applications of influenza virosomes as a delivery system. Human Vaccines, 2(1):1–7.
De Jonge, J. 2006. Use of a dialyzable shortchain phospholipid for efficient solubilization and reconstitution of influenza virus envelopes. Biochimica et Biophysica Acta-Biomembranes, 1758(4):527–536.
Felnerova, D., et al. 2004. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Current Opinion in Biotechnology, 15(6):518–529.
Fukuyama, S., Kawaoka, Y. 2011. The pathogenesis of influenza virus infections: The contributions of virus and host factors. Current Opinion in Immunology, 23(4):481–486.
Glück, R. 1992. Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. Journal of Clinical Investigation, 90(6):2491–2495.
Harandi, A., Medaglini, D. 2010. Mucosal Adjuvants. Current HIV research, 8(4):330–335.
Hatz, C. 2011. Real-life versus package insert: A post-marketing study on adverse-event rates of the virosomal hepatitis A vaccine Epaxal® in healthy travellers. Vaccine, 29(31):5000–5006.
Huckriede, A., et al. 2005. The virosome concept for influenza vaccines. Vaccine, 23(Supple 1):26–38.
Jabbal-Gill, I. 2010. Nasal vaccine innovation. Journal of Drug Targeting, 18(10):771–786.
Kalra, N., et al. 2013. Virosomes: As a Drug Delivery Carrier. American Journal of Advanced Drug Delivery, 1(1):29–35.
Kammer, A. R. 2007. A new and versatile virosomal antigen delivery system to induce cellular and humoral immune responses. Vaccine, 25(41):7065–7074.
Kaneda, Y. 2002. Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Molecular Therapy, 6(2):219–226.
Kapczynski, D. R., Tumpey, T. M. 2003. Development of a virosome vaccine for Newcastle disease virus. Avian Diseases, 47(3):578–587.
Kára, J., Mach, O., Cěrná, H. 1971. Replication of rous sarcoma virus and the biosynthesis of the oncogenic subviral ribonucleoprotein particles (“virosomes”) in the mitochondria isolated from rous sarcoma tissue. Biochemical and Biophysical Research Communications, 44(1):162–169.
Krishnamachari, Y. 2011. Nanoparticle delivery systems in cancer vaccines. Pharmaceutical Research, 28(2):215–236.
Liu, H. 2015. Virosome, a hybrid vehicle for efficient and safe drug delivery and its emerging application in cancer treatment. Acta Pharmaceutica, 65(2):105–116.
Lund, P. E., et al. 2010. Pseudovirions as vehicles for the delivery of siRNA. Pharmaceutical Research, 27(3):400–420.
Mastrobattista, E. 2001. Targeting influenza virosomes to ovarian carcinoma cells. FEBS Letters, 509(1):71–76.
Mischler, R., Metcalfe, I. C. 2002. Inflexal® V a trivalent virosome subunit influenza vaccine: production. Vaccine, 20(Supple 5):17–23.
Miyanohara, A. 2012. Preparation of vesicular stomatitis Virus-G (VSV-G) conjugate and its use in gene transfer. Cold Spring Harbor Protocols, 7(4).
Moghimi, S. M., Szebeni, J. 2003. Stealth liposomes and long circulating nanoparticles: Critical issues in pharmacokinetics, opsonization and protein-binding properties. Progress in Lipid Research, 42(6):463–478.
Morein, B., et al. 1978. Effective subunit vaccines against an enveloped animal virus. Nature, 276(5689):715–718.
Nair, C. S., Sreelekshmi, A. S., Rahiman, C. A. A. A., Krishnan, K., Gopika, G., Nair, T. P., Ajit, U. G. 2020. Virosomes: A groundbreaking revolution in novel drug delivery. International Journal of Research in Pharmaceutical Sciences, 11(4):5809–5820.
Naldi, I., et al. 2014. Novel epigenetic target therapy for prostate cancer: A preclinical study. PLoS ONE, 9(5):1–13.
Nishimura, Y., et al. 2013. Targeting cancer cell-specific RNA interference by siRNA delivery using a complex carrier of affibody-displaying bio-nanocapsules and liposomes. Journal of Nanobiotechnology, 11(1):19.
Noda, T., Kawaoka, Y. 2010. Structure of influenza virus ribonucleoprotein complexes and their packaging into virions. Reviews in Medical Virology, 20(6):380–391.
Okada, Y. 1993. Sendai Virus-Induced Cell Fusion. Methods in Enzymology, 221(C):18–41.
Schoen, P. 1999. Gene transfer mediated by fusion protein hemagglutinin reconstituted in cationic lipid vesicles. Gene Therapy, 6(5):823–832.
Shaikh, S. N., et al. 2019. Overview on virosomes as a novel carrier for drug delivery. Journal of Drug Delivery and Therapeutics, 8(6-s):429–434.
Sharma, R., Yasir, M. 2010. Virosomes: A novel carrier for drug delivery. International Journal of PharmTech Research, 2(4):2327–2339.
Skehel, J. J., Wiley, D. C. 2000. Receptor binding and membrane fusion in virus entry: The influenza hemagglutinin. Annual Review of Biochemistry, 69:531–569.
Stegmann, T. 1987. Functional reconstitution of influenza virus envelopes. The EMBO journal, 6(9):2651–2659.
Suarez, D. L., Schultz-Cherry, S. 2000. Immunology of avian influenza virus: A review. Developmental and Comparative Immunology, 24(2-3):269–283.
Takimoto, T. 2002. Role of the Hemagglutinin-Neuraminidase Protein in the Mechanism of Paramyxovirus-Cell Membrane Fusion. Journal of Virology, 76(24):13028–13033.
Uchida, T. 1979. Reconstitution of lipid vesicles associated with HVJ (Sendai virus) spikes. Purification and some properties of vesicles containing nontoxic fragment A of diphtheria toxin. Journal of Cell Biology, 80(1):10–20.
Wegmann, N. 2002. Targeting HER-2/neu with antirat neu virosomes for cancer therapy. Cancer Research, 62(2):437–444.
Yamada, T., et al. 2003. Nanoparticles for the delivery of genes and drugs to human hepatocytes. Nature Biotechnology, 21(8):885–890.
Zurbriggen, R. 2003. Immunostimulating reconstituted influenza virosomes. Vaccine, 21(9):921–924.
Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.